NICE says final no to Roche's Avastin in metastatic breast cancer
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has published final guidance rejecting Roche's VEGF targeted anticancer Avastin (bevacizumab) for metastatic breast cancer because of doubts over the drug's effectiveness coupled with its high cost.